JSPRW Stock Financial Analysis - Jasper Therapeutics, Inc.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -94.05 MM.
The net income for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -90.92 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-94.05	-90.92
2025-03-31		-82.97	-78.78
2024-12-31		-76.24	-71.27
2024-09-30		-68.68	-63.53
2024-06-30		-68.15	-62.44
2024-03-31		-69.99	-63.93
2023-12-31		-68.86	-64.47
2023-09-30		-64.88	-61.09
2023-06-30		-58.23	-55.41
2023-03-31		-52.37	-49.74
2022-12-31		-51.20	-37.69
2022-09-30		-49.53	-33.53
2022-06-30		-46.90	-25.08
2022-03-31		-43.36	-23.09
2021-12-31		-36.83	-30.64
2021-09-30		-30.71	-31.57
2021-06-30		-26.64	-38.98
2021-03-31		-24.23	-39.99
2020-12-31		-20.68	-31.67

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	-4.89
2024-09-30	-4.67	-4.67
2024-06-30	-4.96	-4.96
2024-03-31	-5.52	-5.52
2023-12-31	-6.18
2023-09-30	-7.11	-7.11
2023-06-30	-8.20	-8.20
2023-03-31	-10.07	-10.07
2022-12-31	-10.33
2022-09-30	-9.20	-9.20
2022-06-30	-8.78	-8.78
2022-03-31	-11.56	-11.56
2021-12-31	-26.89
2021-09-30	-115.56	-115.56
2021-06-30	-38.36	-38.36
2021-03-31	-4.07	-4.07
2020-12-31	-183.08

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -73.48 MM.
The cash from investing activities for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -0.34 MM.
The cash from financing activities for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is 6.52 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-73.48	-0.34	6.52
2025-03-31	-69.71	-0.50	0.54
2024-12-31	-62.60	-0.53	47.88
2024-09-30	-57.95	-0.69	47.27
2024-06-30	-55.88	-0.41	47.30
2024-03-31	-57.47	-0.27	46.81
2023-12-31	-52.07	-0.27	100.97
2023-09-30	-48.23	-0.12	101.27
2023-06-30	-45.90	-0.34	101.23
2023-03-31	-41.98	-0.57	101.55
2022-12-31	-45.86	-0.58	0.06
2022-09-30	-47.80	-1.21	-0.88
2022-06-30	-45.26	-1.45	90.84
2022-03-31	-41.70	-1.50	90.23
2021-12-31	-33.68	-2.43	100.97
2021-09-30	-24.49	-1.72	112.68
2021-06-30	-25.31	-1.25	20.95
2021-03-31	-22.98	-0.96	21.55
2020-12-31	-18.27		11.29

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31

Management Effectiveness

The roa for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -0.69.
The roe for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -0.79.
The roic for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -1.76.
The croic for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -1.55.
The ocroic for Jasper Therapeutics, Inc. - Equity Warrant as of June 30, 2025 is -1.55.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.69	-0.79	-1.76	-1.55	-1.55
2025-03-31	-0.63	-0.70	-1.76	-1.55	-1.55
2024-12-31	-0.75	-0.91	-1.12	-0.24	-0.99
2024-09-30	-0.58	-0.67	-0.74	-0.13	-0.68
2024-06-30	-0.46	-0.51	-0.55	-0.09	-0.50
2024-03-31	-1.33	-1.79	-0.79	0.60	-0.64
2023-12-31	-1.03	-1.28	-0.63	0.54	-0.50
2023-09-30	-0.79	-0.94	-0.49	0.48	-0.40
2023-06-30	-0.79	-0.94	-0.49	0.48	-0.40
2023-03-31	-0.62	-0.73	-0.39	0.46	-0.33
2022-12-31	-0.31	-0.43	-0.65	-0.97	-0.93
2022-09-30	-0.31	-0.43	-0.65	-0.97	-0.93
2022-06-30	-0.96	-1.84	-0.40	0.70	-0.72
2022-03-31	-0.79	-1.06	-0.32	0.65	-0.58
2021-12-31	-1.31	-3.52	-0.42	0.90	-0.47
2021-09-30		-1.50	-0.39	1.06	-0.30
2021-06-30	-1.43	-1.85	-2.33	-0.33	-1.51
2021-03-31	-1.47	-1.90	-1.63	-0.10	-0.94
2020-12-31	-1.16	-1.50	-3.06	-0.68	-1.77

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31

JSPRW Stock Financial Analysis - Jasper Therapeutics, Inc. - Equity Warrant (NasdaqCM) Stock